SkinBioTherapeutics shares suspended on delay to interim results.
SkinBioTherapeutics said on Wednesday that trading in its shares has been suspended after the company failed to publish its interim results by the required deadline under the AIM rules.
SkinBioTherapeutics
01 April 2026 10:50:11
Source: Sharecast
The life sciences group said the suspension took effect from 0830 BST on 1 April, following its failure to announce results for the six months ended 31 December by the end of March.
It said the delay came as a previously-announced board investigation and an independent forensic review by FRP Advisory remained ongoing.
The company said both processes were progressing, and were expected to conclude later in April.
SkinBioTherapeutics said trading in its shares was expected to resume once the interim results were published, and that it would update shareholders on the outcome of the forensic review and board investigation as soon as possible.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate
N/A
ISIN:
N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes
Compare our accounts
If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
